Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer

Stefano Cascinu • 29 Sep 2019
ESMO 2019
Pancreatic Cancer Gemcitabine Nab-paclitaxel
GAP

Stefano Cascinu, University of Modena, Modena, Italy, gives an update on the GAP trial (NCT02043730), a GISCAD Phase II comparative randomized trial of nab-paclitaxel plus gemcitabine in locally advanced, unresectable pancreatic cancer (LAUPC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals